| Ian D Augustin, MD | |
|
1221 Whipple St, Eau Claire, WI 54703-5270 | |
| (715) 838-5222 | |
| Not Available |
| Full Name | Ian D Augustin |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 15 Years |
| Location | 1221 Whipple St, Eau Claire, Wisconsin |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1740412576 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | 60858 (Wisconsin) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Mayo Clinic Health System Eau Claire Hospital | Eau claire, WI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mayo Clinic Health System-northwest Wisconsin Region Inc | 4385553627 | 623 |
News Archive
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.
Patients treated for lumbar spinal stenosis (LSS) with the mild decompression procedure (an alternative to open spinal surgery for many patients), reported sustained improvements in pain and mobility at one year and had no serious adverse events occur, according to the first multi-center one-year post-study follow-up of this patient cohort.
MedImmune, the global biologics research and development arm of AstraZeneca, today announced that it has achieved a significant scientific milestone by publishing three manuscripts in Nature Immunology that advance the understanding of the immune system and highlight underlying mechanisms in two little-understood disease areas - chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus (SLE).
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
› Verified 9 days ago
| Entity Name | Mayo Clinic Health System-northwest Wisconsin Region Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1235588831 PECOS PAC ID: 4385553627 Enrollment ID: O20161109002075 |
News Archive
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.
Patients treated for lumbar spinal stenosis (LSS) with the mild decompression procedure (an alternative to open spinal surgery for many patients), reported sustained improvements in pain and mobility at one year and had no serious adverse events occur, according to the first multi-center one-year post-study follow-up of this patient cohort.
MedImmune, the global biologics research and development arm of AstraZeneca, today announced that it has achieved a significant scientific milestone by publishing three manuscripts in Nature Immunology that advance the understanding of the immune system and highlight underlying mechanisms in two little-understood disease areas - chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus (SLE).
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ian D Augustin, MD 200 1st St Sw, Rochester, MN 55905-0001 Ph: (715) 838-5222 | Ian D Augustin, MD 1221 Whipple St, Eau Claire, WI 54703-5270 Ph: (715) 838-5222 |
News Archive
CytRx Corporation, a biopharmaceutical research and development company specializing in oncology, today announced the initiation of a global Phase 2b clinical trial evaluating aldoxorubicin compared to topotecan in subjects with extensive-stage small cell lung cancer (SCLC) who have relapsed or were refractory to prior chemotherapy.
Patients treated for lumbar spinal stenosis (LSS) with the mild decompression procedure (an alternative to open spinal surgery for many patients), reported sustained improvements in pain and mobility at one year and had no serious adverse events occur, according to the first multi-center one-year post-study follow-up of this patient cohort.
MedImmune, the global biologics research and development arm of AstraZeneca, today announced that it has achieved a significant scientific milestone by publishing three manuscripts in Nature Immunology that advance the understanding of the immune system and highlight underlying mechanisms in two little-understood disease areas - chronic obstructive pulmonary disease (COPD) and systemic lupus erythematosus (SLE).
Immusoft Corporation, a Seattle-Wash.-based cell therapy company, announced today that the U.S. Food and Drug Administration (FDA) has granted it Rare Pediatric Disease Designation (RPDD) for Iduronicrin genleukocel-T, Immusoft's Sleeping Beauty transposon-engineered autologous plasmablasts for the expression and delivery of alpha-L-iduronidase (IDUA) to treat Mucopolysaccharidosis type I (MPS I).
› Verified 9 days ago
Michael Q Milz, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
Eric D Etzel, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
John M Evans, M.D. Anesthesiology Medicare: Medicare Enrolled Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
Frederick P Fetzer, DO Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 2116 Craig Road, Eau Claire, WI 54701 Phone: 715-387-7179 | |
Melissa Kenevan, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1400 Bellinger St, Eau Claire, WI 54703 Phone: 715-838-5222 | |
Steven M Kapla, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-3311 | |
Carmelina Gurrieri, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 1221 Whipple St, Eau Claire, WI 54703 Phone: 715-838-5222 |